Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04392102
Recruitment Status : Not yet recruiting
First Posted : May 18, 2020
Last Update Posted : May 18, 2020
Sponsor:
Information provided by (Responsible Party):
Zai Lab (Shanghai) Co., Ltd.

Brief Summary:
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: ZL-2306(Niraparib) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
Estimated Study Start Date : July 31, 2020
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : July 31, 2023


Arm Intervention/treatment
Experimental: ZL-2306(Niraparib)
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Drug: ZL-2306(Niraparib)
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Other Name: Zejula




Primary Outcome Measures :
  1. Objective Response Rate(ORR) [ Time Frame: Up to 3 years ]
    The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1).


Secondary Outcome Measures :
  1. Duration of Response (DoR) [ Time Frame: Up to 3 years ]
    DoR was defined as the time from first documentation of CR or PR until the time of first documentation of disease progression (PD) as assessed by the Investigator per RECIST (version1.1).

  2. Disease Control Rate (DCR) [ Time Frame: Up to 3 years ]
    Disease control rate was defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST (version1.1). The exact method was used to calculate 95% confidence interval.

  3. Progression Free Survival (PFS) [ Time Frame: Up to 3 years ]
    Progression-free survival was defined as the time from the date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression as assessed by the Investigator per RECIST (version 1.1).

  4. Overall Survival (OS) [ Time Frame: Up to 3 years ]
    Overall Survival was defined as the time from the date of the first dose to the date of death by any cause.

  5. Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE To evaluate the safety and tolerability of niraparib [ Time Frame: Up to 3 years ]
    An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Patients must be female and at least 18 years of age
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Patients must be female and at least 18 years of age
  • 2. Patients must provide written informed consent
  • 3. Patients must be gBRCA mutation or HRD positive
  • 4. Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease.
  • 5. Patients Must have completed 3 or 4 previous chemotherapy regimens.
  • 6. Patients must have measurable disease according to RECIST (v.1.1).
  • 7. Patients must have an Eastern Cooperative Oncology Group(ECOG) performance status of 0 or1
  • 8. Patients must have adequate organ function, defined as follows: a. Absolute neutrophil count≥1500/ul b. Platelets ≥150000/ul c. Hemoglobin≥10g/dL d. Serum creatinine≤1.5X upper limit of normal (ULN)or calculated creatinine clearance≥60ml/min using the Cockcroft-Gault equation e. Total bilirubin≤1.5X ULN OR direct bilirubin≤1X ULN f. Aspartate aminotransferase and alanine aminotransferase≤2.5X ULN unless liver metastases are present, in which case they must be ≤5X ULN
  • 9. Patients must be either postmenopausal, free from menses for>12 months, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from heterosexual activity throughout the study, starting with enrollment through 90 days after the last dose of study treatment
  • 10. Patients must have formalin-fixed, paraffin-embedded tumor samples available form primary or recurrent cancer.
  • 11. Patients must be able to take oral medications and capable of complying with treatment and follow up visit

Exclusion Criteria:

  • 1. Patients who have received other investigational drugs within 4 weeks or 5X t1/2 before first dose of study treatment.
  • 2. Patients have had palliative radiotherapy encompassing>20% of the bone marrow within 3 weeks of the first dose of study treatment.
  • 3. Patients have any known, persistent(>4 weeks),≥Grade 3 anemia, neutrophil count decrease or platelet count decrease during the last chemotherapy.
  • 4. Patients have any known, persistent (>4 weeks), ≥ Grade 3 fatigue during the last chemotherapy.
  • 5. Patients have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
  • 6. Patients have symptomatic uncontrolled brain or leptomeningeal metastases. The patient have new or progressive signs or symptoms related to the CNS disease and not taking a stable dose of steroids or no steroids. A scan to confirm the absence of brain metastases is not required.
  • 7. Patients have known hypersensitivity to the components of niraparib
  • 8. Patient have had major surgery within 3 weeks of fist dose treatment and patient must have recovered form any effects of any major surgery
  • 9. Patients have had diagnosis, detection, or treatment of invasive cancer other than ovarian cancer ≤2 years prior to enrollment(except basal or squamous cell carcinoma of the skin that has been definitively treated)
  • 10. Patients are considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: 1. uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction 2. uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome or any psychiatric disorder that prohibits obtaining informed consent 3. immune deficiency (not including splenectomy) 4. HIV infection or active hepatitis(i.e. hepatitis B with HBV-DNA>500IU/ml or hepatitis C with positive HCV-RNA).
  • 11. Patients have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
  • 12. Patients have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • 13. Patients have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04392102


Contacts
Layout table for location contacts
Contact: Lei Liu 021-61632588 ZL-2306-008@zailaboratory.com

Sponsors and Collaborators
Zai Lab (Shanghai) Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Rutie Yin West China Second University Hospital
Principal Investigator: Xiahua Wu Fudan University
Principal Investigator: Hong Zheng Beijing Cancer Hospital
Principal Investigator: Ge Lou Harbin Medical University
Principal Investigator: Lingying Wu Chinese Academy of Medical Sciences
Principal Investigator: Hongmin Pan Sir Run Shaw Hospital, school of medicine, Zhejiang University
Principal Investigator: Zhongqiu Lin Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Layout table for additonal information
Responsible Party: Zai Lab (Shanghai) Co., Ltd.
ClinicalTrials.gov Identifier: NCT04392102    
Other Study ID Numbers: ZL-2306-008
First Posted: May 18, 2020    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Niraparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents